Roseburia

A genus of Gram-positive, obligate anaerobic, flagellated bacteria within the lachnospiraceae family that ranks among the most important butyrate producers in the human gut. Key species include R. intestinalis and R. hominis. Roseburia is consistently depleted across inflammatory, metabolic, and neurodegenerative diseases, and its sensitivity to metal stress places it at the center of the gut metal microbiome axis.

Butyrate Production and Anti-inflammatory Mechanisms

  • Produces butyrate as its primary fermentation end-product from dietary fiber, particularly via the butyryl-CoA:acetate CoA-transferase pathway [1].
  • Butyrate from Roseburia acts through multiple anti-inflammatory pathways:
  • HDAC inhibition: butyrate inhibits histone deacetylases in colonocytes and immune cells, promoting anti-inflammatory gene expression and Treg differentiation.
  • GPR109A signaling: butyrate activates the GPR109A receptor on colonic epithelial cells and dendritic cells, inducing IL-10 production and suppressing NF-kB-mediated inflammation.
  • Barrier maintenance: supports tight junction integrity (ZO-1, occludin, claudin-1) and maintains colonocyte oxygen consumption, preserving the anaerobic lumen.
  • Flagellin from R. hominis specifically activates TLR5 signaling in a beneficial context, promoting mucosal immune homeostasis rather than inflammation [2].

Depletion Across Disease States

Roseburia depletion is among the most reproducible microbiome findings in human disease:

  • Cardiovascular disease: depleted in ACVD patients in the Jie et al. study; CAG4 containing Faecalibacterium and Roseburia was closely related to 10 serum metabolite modules and important for maintaining normal coronary physiology [3] [4] [5].
  • Hypertension: bidirectional Mendelian randomization links reduced Roseburia to elevated blood pressure [6].
  • IBD: reduced in both Crohn's disease and ulcerative colitis; inversely correlated with disease activity scores [7].
  • Multiple sclerosis: depleted alongside other lachnospiraceae members; loss reduces SCFA-mediated immune modulation [8].
  • Colorectal cancer: reduced; butyrate loss diminishes anti-tumorigenic HDAC inhibition in colonocytes [9] [10].
  • Type 2 diabetes: depleted; inversely correlated with HbA1c and insulin resistance.
  • Chronic kidney disease: depleted across CKD progression, contributing to loss of SCFA-mediated renal protection [11] [12] [13].
  • Endometriosis: Roseburia sp. CAG:45 decreased in endometriosis [14].
  • Parkinson's disease: depleted alongside other SCFA producers as part of the metal-driven dysbiosis framework [15] [16] [17].
  • Schizophrenia: Roseburia is significantly depleted in schizophrenia patients (p=0.023), and its abundance is negatively correlated with fMRI regional homogeneity (ReHo) indices in the right superior temporal cortex, right middle temporal cortex, and left cuneus — brain regions showing decreased ReHo in schizophrenia [2].

Metal Sensitivity

  • Roseburia is particularly sensitive to heavy metal stress, more so than many other gut commensals.
  • Iron-sulfur cluster enzymes in the butyrate synthesis pathway are vulnerable to disruption by cadmium, lead, and other toxic metals that compete for iron binding sites.
  • Under metal-stressed conditions, Roseburia is outcompeted by siderophore-producing enterobacteriaceae that aggressively scavenge iron, compounding its depletion.
  • This metal sensitivity positions Roseburia as an early biomarker for environmental metal exposure effects on the gut microbiome.

Key Metabolites

  • Butyrate — primary output; HDAC inhibitor, colonocyte fuel, Treg inducer.
  • Acetate — secondary fermentation product; feeds acetogenic pathways.
  • Formate — minor product; serves as electron carrier in anaerobic cross-feeding.
  • Flagellin — immunostimulatory protein from R. hominis that promotes beneficial TLR5 signaling.

Key Sources

Connections

  • lachnospiraceae — parent family; Roseburia is a flagship genus
  • faecalibacterium prausnitzii — co-depleted partner; together represent the core butyrate-producing guild
  • ruminococcus — receives starch degradation products from R. bromii for butyrate conversion
  • cardiovascular disease — CAG4 (Faecalibacterium/Roseburia) loss correlated with CAD severity
  • crohns disease — depleted; inversely correlated with disease activity
  • colorectal cancer — butyrate loss reduces HDAC-mediated tumor suppression
  • parkinsons disease — depleted in metal-driven dysbiosis framework
  • iron — Fe-S clusters essential for butyrate production; iron competition from pathogens
  • cadmium — particularly sensitive to Cd-induced depletion
  • dysbiosis — one of the most reliably depleted genera across disease states
  • inflammation — butyrate/HDAC/GPR109A anti-inflammatory axis
  • gut metal microbiome — metal sensitivity makes it an early indicator of metal-induced dysbiosis

References (17)

  1. . ross 2024 diet gut microbiome interplay health disease
  2. . li 2021 gut microbiome brain structure function schizophrenia
  3. . jie 2017 gut microbiome acvd
  4. . liu 2019 gut microbiome metabolism cad severity
  5. . almeida 2023 gut microbiota cardiovascular axis
  6. . li 2023 gut microbiome hypertension bidirectional mr
  7. . li 2020 polyphenols gut microbiota ibd synergy
  8. . boussamet 2024 oral microbiota metabolite signature ms
  9. . vipperla 2016 diet microbiota dysbiosis colorectal cancer
  10. . van dingenen 2023 gut microbiome radio immunotherapy crc
  11. . tang 2023 gut microbiome tango ckd progression
  12. . yasuno 2024 dysbiosis gut microbiota ckd
  13. . zhang 2023 metagenome esrd microbiome uremic toxins
  14. . perez prieto 2024 gut microbiome endometriosis 1000 cohort
  15. . pendergrass 2026 microbial metallomics parkinsons ferroptosis
  16. . houser 2019 microbiome inflammation disease progression parkinsons
  17. . sampson 2024 microbiome signature parkinsons multicohort